report-anti diabetic medication

8/9/2019 Report-Anti Diabetic Medication

1/26

1

STUDENT COLLOQUIUM REPORT ON PRODUCT SURVEY

OF

ANTI-DIABETIC MEDICATION

Prepared By: - GROUP NO. 7

NIRAV PATEL

BHUPENDRASINH ZALA

LAHERU PUNIT

HIREN DARJI

KEYUR SAVALIYA

MITESH SHAH


2/26

2

AUTHORISATION

The Report is submitted as a partial fulfillment of the requirement program of MBA

program of STEVENS BUSINESS SCHOOL, AHMEDABAD.


3/26

3

ACKNOWLEDGEMENT

__________________________________________________________________________________________________________________

It is indeed an opportunity to prepare this report. Preparation of such type of report callsfor intellectual nourishment, professional help and encouragement from many areas.

I would like to thank Stevens Business School for the compulsion of this mostwonderful aspect of our MBA curriculum without which knowledge of managementstudies is incomplete and futile.

I would like to thank and express my gratitude to Dr. Himani Joshi for providing us herguidance and co- operation.

Lastly, I would like to thank to all those who had helped us directly or indirectly incompleting this project successfully.


4/26

4

SR NO. PARTICULAR PAGE NO.

1 Introduction 05

2 Product Range 07

3 Market Analysis 13

4 Advertisement of Anti-DiabeticDrugs

22

5 Distribution Channel 23

7 Pricing 24

8 Conclusion 24

9 Summary 25

10 Reference 26


5/26

5

WHAT IS THE DIABETES MELLITUS?

DEFINITION

Diabetes mellitus (DM) is defined as a metabolic disorder of multiple etiologiescharacterized by chronic hyperglycemia with disturbances of carbohydrate, protein, andfat metabolism resulting from defects in insulin secretion, insulin action, or both.

TYPES OF DIABETES

1. Type I diabetes

A. Immune mediatedB. Idiopathic

Formerly known as insulin-dependent diabetes mellitus (IDDM) or juvenile-onsetdiabetes mellitus, is caused by autoimmune destruction of the -cells of the

pancreas, rendering the pancreas unable to synthesize and secrete insulin.

It usually occurs before the age of 30, has a short asymptomatic period, and runs asevere clinical course.

2. Type II diabetes

Formerly known as non-insulin-dependent diabetes mellitus (NIDDM) or adultonset diabetes, results from a combination of insulin resistance and inadequateinsulin secretion.

Onset is usually after the age of 30 years and the prevalence increases with age.3. Other specific types

A. Genetic defects of b-cell functionB. Genetic defects in insulin actionC. Diseases of the exocrine pancreas

D. EndocrinopathiesE. Drug- or chemical-inducedF. InfectionsG. Uncommon forms of immune-mediated diabetes (IMD)H. Other genetic syndromes sometimes associated with diabetes

4. Gestational Diabetes Mellitus (GDM)


6/26

6

ANTI-DIABETIC AGENTS

WHAT ARE THE ANTI-DIABETIC AGENTS ?

A drug which reduces the blood glucose level by enhancing the insulin secretion or by

increasing the glucose metabolism.

CLASSIFICATION OF ANT DIABETIC DRUGS

Anti-diabetic drugs can be classified into two categories:

1. Insulin injections: Mostly used on serious cases of diabetes.

2. Oral ant diabetic drugs: Suitable for most adult patients. There are two common types

of oral ant diabetic drugs:

a) Sulphonylureas: They increase insulin secretion. Common examples arechlorpropamide, glibenclamide and gliclazide.

b) BiguanidesMetformin is an example.

These drugs can only be sold on doctors prescription in registered dispensaries.


7/26

7

PRODUCT RANGE

Anti diabetic drugs are available in various dosage forms and in various quantity of

active pharmaceutical ingredient.

The various available dosage forms are,

-Control release tablets-Sustain release tablets-Extended release tablets-Semi tablets-Capsules-Parental preparation (Subcutaneous rout of administration)

ANTI DIABETIC TABLETS

The active pharmaceutical ingredient which are used as anti diabetic tablets are as below

-Chlorpropamide-Tolbutamide-Glibenclamide-Glipizide-Glicazide-Glimepride

-Phenformin-Metformin-Acarbose-Repaglide-Rosiglitazone-Pioglitazone-Combination Of Gliclazide And Rosiglitazone-Combination of Metformin and Glibenclamide-Combination of Metformin and Glipizide-Combination of Metformin and Gliclazide

-Combination of Metformin and Glimepride-Combination of Metformin and Rosiglitazone-Combination of Metformin and Pioglitazone-Combination of Pioglitazone and Glimepride


8/26

8

The quantity of API per tablet is also vary according to type of API and the available

tablets contains following range of quantity

0.5mg, 1mg, 1.25mg, 2mg, 3mg, 4mg, 5mg, 6mg, 8mg, 10mg, 15mg, 30mg, 40mg,

50mg, 80mg, 100mg, 120mg, 125mg, 250mg, 850mg, 1000mg.

ANTI-DIABETIC DRUGS ACCRODING TO COMPANY NAME

COMPANY

NAME

MARKET

NAME ACTIVE PHARMACEUTICAL INGREDIENT

QUANTITY OF ACTIVE

INGREDIENT

US VITAMINEBOVINEFASTACT NEUTRAL INSULIN (SOLUBLE)

US VITAMINE GLYCOR GLICLAZIDE 80MG

US VITAMINE GLYBORAL GLIBENCLAMIDE 2.5MGUS VITAMINE GLYBORAL GLIBENCLAMIDE 5MG

US VITAMINE GLYNASE GLIPIZIDE 2.5MG

US VITAMINE GLYNASE GLIPIZIDE 5MG



US VITAMINE GLYCOMET PREPARATION OF METFORMIN 500MG

US VITAMINE GLYCOMET PREPARATION OF METFORMIN 850MG

US VITAMINE GLYCOMET PREPARATION OF METFORMIN 1GM

US VITAMINE DUOTOROLCOMBINATION OF METFORMIN &GLIBENCLAMIDE METFORMIN 500MG

US VITAMINE DUOTOROLCOMBINATION OF METFORMIN &GLIBENCLAMIDE GLBENCLAMIDE 5MG

US VITAMINE GLYNASE MF COMBINTION OF METFORMIN & GLIPIZIDE METFORMIN 500MG

US VITAMINE GLYNASE MF COMBINTION OF METFORMIN & GLIPIZIDE GLIPIZIDE 5MG

US VITAMINEPROCINE-FASTACT NEUTRAL INSULIN (SOLUBLE)

US VITAMINEBOVINELONACT ISOPHANE INSULIN (NPH)

US VITAMINEHUMANLONGACT ISOPHANE INSULIN (NPH)

US VITAMINEBOVINE-MIXACT PREMIXED BIPHASIC INSULIN

US VITAMINEHUMAN-MIXACT PREMIXED BIPHASIC INSULIN

US VITAMINEPORCINEMIXACT PREMIXED BIPHASIC INSULIN

SUN PHARMA GLUCOSAFE GLIBENCLAMIDE 2.5mg

SUN PHARMA GLYPRIDE GLIMEPRIDE 1MG



9/26

9


SUN PHARMA GLUCOREDCOMBINATION OF METFORMIN &GLIBENCLAMIDE METFORMIN 400MG

SUN PHARMA GLUCOREDCOMBINATION OF METFORMIN &GLIBENCLAMIDE GLIBENCLAMIDE 2.5MG

SUN PHARMA GLUCOREDCOMBINATION OF METFORMIN &GLIBENCLAMIDE METFORMIN 500MG

SUN PHARMA GLUCORED COMBINATION OF METFORMIN &GLIBENCLAMIDE GLIBENCLAMIDE 5MG

SUN PHARMA PIOGLIT-MFCOMBINATION OF METFORMIN WITHPIOGLITAZONE METFORMIN 500MG

SUN PHARMA PIOGLIT-MFCOMBINATION OF METFORMIN WITHPIOGLITAZONE PIOGLITAZONE 7.5MG

SUN PHARMA REZULT ROSIGLITAZONE 2MG



SUN PHARMA PIOGLIT PIOGLITAZONE 15MG

SUN PHARMA PIOGLIT PIOGLITAZONE 30MG

TORRENTPHARMA AZUKON GLICLAZIDE 80MG

TORRENTPHARMA AZUKON-MR GLICLAZIDE 30MG

TORRENTPHARMA AZULIX GLIMEPRIDE 1MG

TORRENTPHARMA AZULIX GLIMEPRIDE 2MG

TORRENTPHARMA DIBETA-SR 500 PREPARATION OF METFORMIN 500MG

TORRENTPHARMA DIBETA-SR 501 PREPARATION OF METFORMIN 1GM

TORRENTPHARMA AZUKON-M COMBINATION OF METFORMIN &GLICLAZIDE METFORMIN 500MG

TORRENTPHARMA AZUKON-M

COMBINATION OF METFORMIN &GLICLAZIDE GLICAZIDE 80MG

TORRENTPHARMA

AZULIX 1/2 MFFORTE

COMBINATION OF METFORMIN WITHGLIMEPRIDE METFORMIN 1000MG

TORRENTPHARMA

AZULIX 1/2 MFFORTE

COMBINATION OF METFORMIN WITHGLIMEPRIDE GLIMEPRIDE 1MG

TORRENTPHARMA ENSELIN 2MF

COMBINATION OF METFORMIN WITHROSIGLITAZONE METFORMIN 500MG

TORRENTPHARMA ENSELIN 2MF

COMBINATION OF METFORMIN WITHROSIGLITAZONE ROSIGLITAZONE 2MG

TORRENT

PHARMA ENSELIN-4MF

COMBINATION OF METFORMIN WITH

ROSIGLITAZONE METFORMIN 500MGTORRENTPHARMA ENSELIN-4MF


TORRENTPHARMA

ENSELIN 2MFFORTE


TORRENTPHARMA

ENSELIN 2MFFORTE


TORRENTPHARMA

ENSELIN 4MFFORTE


TORRENT ENSELIN 4MF COMBINATION OF METFORMIN WITH ROSIGLITAZONE 4MG


10/26

10

PHARMA FORTE ROSIGLITAZONE

TORRENTPHARMA EUREPA REPLAGLINIDE 0.5MG



TORRENTPHARMA ENSELIN ROSIGLITAZONE 2MG



ANTI-DIABETIC PARENTAL PREPARATIONS

Main API for parental preparation are,

-Neutral Insulin (Soluble)-Isophane Insulin (NPH)-Insulin Zinc Suspension (Lente Insulin)-Premixed Biphasic Insulin-Insulin Lispro-Insulin Glargine

The available quantities of API in parental preparation are

-40i.u/ml (insulin units/ml)-100i.u/ml (insulin units/ml)

The companies which manufacture parental preparation are

-ELI LILY-NOVO NORDISK-RANBAXY-CADILA PHARMA

-SARABHAI

The major players in this market are ELI LILY and NOVO NORDISK.


11/26

11

ANTI DIABETIC DRUGS ACCORDING TO COMPANY NAME

COMPANY NAME

MARKET

NAME

ACTIVE

PHARMACEUTICAL

INGREDIENT

QUANTITY OF ACTIVE

INGREDIENT MRP(rs)

ELI LILYPHARMACEUTICAL

HUMANSULIN-R

NEUTRAL INSULIN(SOLUBLE) 40i.u/ml 158


HUMANSULIN-R



HUMANSULIN-R


ELI LILYPHARMACEUTICAL HUMINSULIN-N ISOPHANE INSULIN (NPH) 40i.u/ml 158

ELI LILYPHARMACEUTICAL HUMINSULIN-N ISOPHANE INSULIN (NPH) 100i.u/ml 352-358

ELI LILYPHARMACEUTICAL HUMINSULIN-N ISOPHANE INSULIN (NPH) 100i.u/ml 350

ELI LILYPHARMACEUTICAL HUMINSULIN-L

INSULIN ZINC SUSPENSION(LENTE INSULIN) 40i.u/ml 158


HUMINSULIN30:70

PREMIXED BIPHASICINSULIN 40i.u/ml 350


HUMINSULIN30:70



HUMINSULIN30:70



HUMINSULIN50:50



HUMINSULIN50:50


ELI LILYPHARMACEUTICAL HUMALOG INSULIN LISPRO 40i.u/ml 158

ELI LILYPHARMACEUTICAL HUMALOG INSULIN LISPRO 100i.u/ml 350

NOVO NORDISKPHARMA ACTRAPID


NOVO NORDISKPHARMA

ACTRAPID HMPENFILL


NOVO NORDISKPHARMA

ACTRAPIDNOVOLET

NEUTRAL INSULIN(SOLUBLE) 3*5ML (PACK OF 5)

NOVO NORDISK

PHARMA

HUMAN

ACTRAPID

NEUTRAL INSULIN

(SOLUBLE) 40i.u/ml 150NOVO NORDISKPHARMA

HUMANACTRAPID


NOVO NORDISKPHARMA

NOVORAPIDFLEXPEN

NEUTRAL INSULIN(SOLUBLE) 300U/FLEXPEN

NOVO NORDISKPHARMA

HUMANINSULATARD ISOPHANE INSULIN (NPH) 40i.u/ml 150

NOVO NORDISKPHARMA INSULATARD ISOPHANE INSULIN (NPH) 40i.u/ml 150


12/26

12

NOVO NORDISKPHARMA

INSULATARDNOVOLET ISOPHANE INSULIN (NPH)

NOVO NORDISKPHARMA

INSULATARDHM PENFILL ISOPHANE INSULIN (NPH) 296

NOVO NORDISKPHARMA

HUMANMONOTARD


NOVO NORDISKPHARMA

HUMANMONOTARD


NOVO NORDISKPHARMA LENTARD 40


NOVO NORDISKPHARMA

HUMAN-MIXTARD


NOVO NORDISKPHARMA

HUMAN-MIXTARD


NOVO NORDISKPHARMA MIXTARD


NOVO NORDISKPHARMA

MIXTARD 30HM PENFILL


NOVO NORDISKPHARMA

MIXTARD 50HM PENFILL


NOVO NORDISKPHARMA

MIXTARD 30NOVOLET

PREMIXED BIPHASICINSULIN

NOVO NORDISKPHARMA

MIXTARD 50NOVOLET

PREMIXED BIPHASICINSULIN

NOVO NORDISKPHARMA

NOVOMIX 30FLEXPEN

PREMIXED BIPHASICINSULIN 300U/FLEXPEN

NOVO NORDISKPHARMA

GLUCAGENHYPOKIT GLUCAGON 1MG/ML


13/26

13

MARKET ANALYSIS

THE INSULIN MARKET - MOVING WITH THE TIMES

Injectable insulin is under threat. The imminent arrival of non-injectable insulin could

finally topple the big insulin players off their comfortable perch, in the $7 bn industrythat has seen little real competition until now.

For decades afterinsulin was first launched, the two pharma giants Eli Lilly and NovoNordisk, enjoyed a free reign in the world market, although Lilly remained dominant.

This is because unlike the drugs in most other big dollar industries, insulin is not achemical compound, but a biological compound.

No laws exist to deal with the issue of biological patents and because of this most

companies found the existing insulin patents too hard to challenge.

The first real change came when Sanofi Aventis managed to grab a chunk of the marketin 2000 with the introduction of its novel once-daily long acting human insulin, Lantus,achieving worldwide revenue of $290 m in the first two years.

The next change came more recently when Novo finally won the bitter tug-of-war andbroke free from Lilly after launching a series of novel insulin analogs that provedpopular with patients.

The continued rollout of its insulin analogs, coupled with the increase of its US-based

sales force to 600 reps finally knocked Lilly from the top spot and Novo Nordiskmovedinto a US leadership position for the first time in late 2005.

With the approval of its new long-acting insulin analogue, Levemir, in June last year,Novo Nordisk also became the first company with a full range of insulin analogues inthe US.

Shortly after, Eli Lilly admitted defeat and announced the discontinuation of its older-style Iletin II Pork Insulin, Humulin U Ultralente and Humulin L Lente insulin products.

However, Novo may have won the battle for now but its reign may only be short lived,

as the anticipated launch ofnon-injectable insulin in the next few years is bound toshake up this multibillion-dollar-a-year market once again.

This is because an alternative to injections has been long-awaited by the 40-50 millionType 2 and 10 million type 1 diabetics worldwide who need insulin therapy but dreamof one day abandoning their needles.
http://www.in-pharmatechnologist.com/content/search?SearchText=insulin&FromNewshttp://www.lilly.com/http://www.novonordisk.com/http://www.novonordisk.com/http://www.sanofi-aventis.com/http://www.in-pharmatechnologist.com/content/search?SearchText=Novo+Nordisk&FromNewshttp://www.in-pharmatechnologist.com/content/search?SearchText=Eli+Lilly&FromNewshttp://www.in-pharmatechnologist.com/content/search?SearchText=non-injectable&FromNewshttp://www.in-pharmatechnologist.com/content/search?SearchText=non-injectable&FromNewshttp://www.in-pharmatechnologist.com/content/search?SearchText=Eli+Lilly&FromNewshttp://www.in-pharmatechnologist.com/content/search?SearchText=Novo+Nordisk&FromNewshttp://www.sanofi-aventis.com/http://www.novonordisk.com/http://www.novonordisk.com/http://www.lilly.com/http://www.in-pharmatechnologist.com/content/search?SearchText=insulin&FromNews


14/26

14

More importantly, the thought of having to self-inject several times a day results inmany diabetics not taking their insulin treatment regularly, leaving them at risk ofserious health complications such as blindness, cardiovascular and circulatory problemsand kidney failure.

Therefore, if successful non-injectable insulin products are launched, analysts predict

sales could exceed $5 bn by the end of this decade.

In a pre-emptive move to capture the future insulin market and prevent current marketshare erosion, Novo, Lilly and Sanofi/Pfizer have been working with biotech and drugdelivery companies for years to develop various forms of insulin that is inhaled by thelungs and product launches are now imminent.

As Novo's reign comes under siege, the once sluggish insulin industry is poised toexplode in a flurry of activity, as Lilly attempts to claw its way back to the top andSanofi/Pfizer looks to blow them both out of the water with Exubera, the product likelyto hit Pharmacy shelves by the middle of this year.

68 percent of USV's business is contributed by the India operations and the rest byexport of APIs and Generics.

USV market its products globally to over 40 countries.

In financial year of 2008-09 USV's sales were Rs. 8,451 million.

USV's Indian business contributes to 67 percent of its sales.

In India USV is recognised for its leadership in the areas of diabetes where USV is a

leader by Rx and value in the oral segment.

Inhaled Insulin devices were earlier thought to make a big success, but Pfizers Exuberawas a big flop in 2006 with estimated revenues of 1/10th as what had been earlier

projected.

In 2005 use of Non-U100 insulin was very popular in India.

Anti-diabetic drug Actos (product of Takeda) control the highest market share of 40.5percent globally from the period of October 2007 to October 2008.

Diabetes drug Actos sale was highest it was more than twice the sale of its nearestcompetitor Januvia for the period of October 2007 to October 2008.


15/26

15

China insulin and analogue market grow by 55.8 percent in the year 2007 compared to2006.

Russia insulin market is expected to cross the mark of US$ 600 Million by 2010.

In 2004 Mexico insulin market was just 1 percent of its total pharmaceutical market.

The US has the dominant share in the global diabetes market, with 49.6% of 2005global sales.


16/26

16

GLOBAL INCREASE IN NUMBER OF DIABETIC PATIENTS

0

50

100

150

200

250

300

350

170205

246300

350

NUMBER OF DIABETIC PATIENTS

AMOUNT IN MILLIONS

GLOBAL MARKET FOR ALL ANTI DIABETIC DRUGS


17/26

17

INSULIN MARKET IN US - 2009

INSULIN MARKET IN INDIA-2009


18/26

18

GLOBAL INSULIN MARKET-2009

MARKET SHARE OF VARIOUS FORMS OF INSULIN PREPARATION-2009


19/26

19

GLOBAL MARKET SHARE OF INSULIN PEN-2009

SALE OF ANTI DIABETIC DRUGS IN 2009


20/26

20

MAJOR PLAYERS IN ORAL HYPOGLYCEMIC DRUGS

MAJOR MARKET PRODUCTS OF USV


21/26

21

MAJOR MARKET PRODUCTS OF SUN PHARMA


22/26

22

ADVERTISEMENT OF ANTI-DIABETIC AGENTS

Advertisement of the Any Pharmaceutical Drugs can not be done directly to the public

place or through the television or radio. It is possible with the following respectivemanner only.

1. Medical representative :Most of the advertisement of Pharmaceutical Product is carried out by thismethod. A qualified person who has an adequate knowledge of the drugs will tothe registered Medical Practitioner and gives detail information to him with full

protocol about the drugs.

2. MagazineVarious pharmacuetical magazinws are available which maintaine up datedreports of pharma industry as well as as pharma product. Such kind of magazine

provide complete data about the pharma company and its products. So, companygive there advertisements in such kind of magazines.Various pharma magazines are

Pharmatimes,Pharma AtoZ,Pharmabuzz,Pharmainfo,Journal of pharmacy research

3. Web siteDrug can be advertisement through website like

www.pharmaall.comwww.pharmainfo.netwww.pharmabuzz.comwww.jpr.com
http://www.pharmaall.com/http://www.pharmainfo.net/http://www.pharmabuzz.com/http://www.jpr.com/http://www.jpr.com/http://www.pharmabuzz.com/http://www.pharmainfo.net/http://www.pharmaall.com/


23/26

23

4. Free sampleCompany distributes the free samples of medicine in hospitals or to the registeredMedical practitioner.

5.

Broachers

Company prepares the broachers of particular product and distribute amongphysicians.

6. Free check up camp and counseling :Company organizes camp for free check up and also advice for medication.

7. Pharmaceutical fair like IPC, Pharmacy India 2009Many companies participate in the pharma fair like Indian pharmaceuticalcongress and pharmac india and put thire stalls and promote their products.

8. Seminars :In this type of the particular method information of the Pharmaceutical Product isgiven to the Medical Practitioner, Wholesalers and Retailers by conducting theSeminar on that Particular product

DISTRIBUTION CHANNEL

1. CompanyDepoStockistRetailer - Customer2. CompanyWholesallerStockist- Retailer- Customer3. CompanyRetailorCustomer4. CompanyHospitalCustomer


24/26

24

PRICING

Anti diabetic drugs are covered in Life saving drugs and under Drug Price ControlOrder (DPCO) and thats why the margin on this kind of product is limited to 10 to 15%

for tablet preparations.

CONCLUSION

The increasing number of diabetes patients globally is proving a boon for diabetes drugs

market. The number of diabetic patients in the world is estimated to reach at more than

250 Million in 2010. The governments worldwide are taking initiatives on various

research and development projects in order to improve drug delivery techniques. This

may be beneficial in terms of growing consumer base in developing countries like India

and China. The main requirement of present market is to develop efficient deliverymethods at low cost and this may change the scenario of the industry. Most of the

insulin today is available in inject able form through syringes, pens, pumps and needle-

free devices; however, the pain and inconvenience caused by most of these devices are

driving pharmaceutical companies to discover other painless modes of insul in

delivery, particularly oral methods. But, on the other hand, a low cost factor is also

playing a major part in success of new drug delivery methods. Now a days number of

diabetes patients has been increasing in India. We have to go for product development.

So company has to find convenient way of delivery and molecule development.


25/26

25

SUMMARY

There are number of pharmaceutical companies playing in the Indian retail and

wholesale pharma industry. There are national and international players are the

constituents of Indian pharma industry.Here in this project report we have choosen

antidiabetic drug type and presented information regarding various companies market

shareprice discrimination of the drugs oral and injectable.


26/26

26

REFERENCES

1. William H. Herman, Ronald E. Aubert, Mohammad A. Ali, Edward S. Sous andAhmed Badran. Diabetes mellitus in Egypt: risk factors, prevalence and future burden.

EMHJ Volume 3, Issue 1, 1997, Page 144-148.

2. Roberts AB, Baker JR, Metcalf P, et al. Fructosamine compared with a glucose loadasa screening test for gestational diabetes. Obstet Gynecol 1990;76:773-775.

3. Business insights

4. 12.17 Company Market Share (%) For Insulin Products for the EuropeanMarket

5. Singer DE, Coley CM, Samet JH, et al. Tests of glycemia in diabetes mellitus. AnnIntern Med 1989;110:125-137.

6. Indian drug review 2008-2009

report-anti diabetic medication

Documents